medRxiv
September 11, 2026
Srdjan Sumarac, Tristan Lawson, Leonardo Favi Bocca et al.
preprint
Ketamine and subcallosal cingulate (SCC) deep brain stimulation (DBS) have each shown antidepressant effects in treatment-resistant depression, yet how ketamine modulates SCC physiology during chronic stimulation remains poorly understood. We analyzed 5,907 hours of bilateral SCC sensing, 485 participant-triggered recordings across 193 days, 47 ketamine dosing episodes, and an in-clinic...
medRxiv
September 10, 2026
Mori Krantz, Mark C. Haigney, Mary Ross Southworth et al.
preprint
Background: Several Schedule I substances have demonstrated potential benefits for refractory psychiatric conditions and addiction. Some have been legalized at the state level, while others like kratom (mitragynine) are available over-the-counter in some states and illegal in others. A recent presidential executive order directs certain federal agencies to accelerate development and facilitate...
medRxiv
September 2, 2026
preprint
In Vitro Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner
medRxiv
August 31, 2026
Jonathan Huntley, Benjy Barnett, Daniel Bor et al.
preprint
Despite extensive knowledge of the progressive sequence of cognitive and functional deficits in Alzheimer's Disease (AD), the impact of neurodegeneration on the conscious experience of patients remains largely unexplored. Understanding how the content of consciousness, particularly perceptual awareness, changes with the progression of AD is crucial to enable meaningful person-centred care. This...
medRxiv
August 27, 2026
Krista Whitley, Kai Davide Castellarin, Kumar Dave et al.
preprint
Abstract Ayahuasca use has expanded beyond its traditional Amazonian contexts, yet prospective longitudinal data examining depressive symptoms following naturalistic use in the United States remain limited. We conducted an interim analysis of an ongoing prospective observational cohort of adults participating in naturalistic ayahuasca use in Las Vegas, Nevada. Depressive symptoms were assessed...
medRxiv
August 22, 2026
Tobias P. Whelan, Mihail Dimitrov, Lucas G. S. França et al.
preprint
Importance There is increasing interest in the potential of psilocybin to treat mental health and neurodevelopmental conditions. At high doses, the therapeutic benefit of psilocybin is linked to greater functional connectivity or integration between large-scale brain networks which underpin mood, emotion and cognition. However, it is unknown how the brain responds to psilocybin in autism - a...
medRxiv
August 19, 2026
H. V. Harrison, M. Gaillard, R. Cook et al.
preprint
Introduction: In 2020, Oregon became the first US state to legalize state-regulated psilocybin services. This study aims to examine: 1) the clinical and demographic characteristics, 2) psilocybin use motivations, and 3) differences in preparedness among patients seeking care in a Oregon- based pilot consult service specializing in psilocybin risk reduction. Methods: This retrospective chart...
medRxiv
August 14, 2026
Annette M Braxton, Christina Driver, Daniel F. Hermens et al.
preprint
Abstract Major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are prevalent, chronic, and disabling mental health conditions which are difficult to treat. Ketamine has demonstrated effect for improving depression and PTSD symptoms independently but reports often overlook focused comorbid improvement of these symptoms within individuals. To address this, we assessed...
medRxiv
August 12, 2026
Scott M. Thompson, Devin P. Effinger, Andrew M Novick et al.
preprint
Abstract Oregon (OR) and Colorado (CO) were the first states to enact regulations for provision of psilocybin with support of licensed ‘facilitators.’ As more states and countries adopt similar policies, informed public policy decisions require that client characteristics and rationale for using psilocybin, psilocybin dosing practices, mental health outcomes, and adverse events are understood....
medRxiv
July 23, 2026
Aaron M. Eisen, Philippe Goldin, Jyoti Mishra et al.
preprint
Abstract Emerging evidence suggests that adults with a history of early life adversity (ELA), while more susceptible to psychopathology, may also be particularly sensitive to the benefits of contemplative practices. In the present study, we examined whether ELA was associated with greater mental health benefits following a contemplative-based social resilience training program, administered as...
medRxiv
July 22, 2026
Kenneth Shinozuka, Clayton Olash, Tracy Han et al.
preprint
Preliminary evidence suggests that the combination of magnesium and ibogaine, an atypical psychedelic, may be a promising treatment for post-traumatic stress disorder (PTSD), opioid use disorder, and traumatic brain injury (TBI). The "mystical" experience elicited by ibogaine, which is characterized by feelings of awe, selflessness, and transcendence, is correlated with improvements in PTSD...
medRxiv
July 19, 2026
Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al.
Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10-25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be separated from its hallucinogenic activity remains unresolved. To address this gap, we conducted a Phase...
medRxiv
July 17, 2026
Amandine Fernandez, Alexandre Foncelle, Hélène Meunier et al.
Introduction Auto-Induced Cognitive Trance (AICT) is a non-ordinary state of consciousness (NOSC) that can be accessed by will alone once a standardised self-induction procedure has been learnt. The first research publication on AICT dates back only ten years, meaning that research on this phenomenon is still in its infancy. Previous reports concerning the phenomenology and neurophysiology of...
medRxiv
July 14, 2026
Kristian Stefanov, Joel T. Parkinson, Flavia Sunzini et al.
Abstract Nociplastic pain represents a major burden across immune-mediated inflammatory diseases (IMIDs). It is hypothesised, but not yet demonstrated, that peripheral inflammation promotes nociplastic pain by bottom-up sensitisation of the central nervous system (CNS). In rheumatoid arthritis (RA), a prototypic IMID, we used ultra–high field (7T) brain resting-state functional MRI to evaluate...
medRxiv
July 10, 2026
Lada Kohoutová, Jevita Potheegadoo, Léa F Duong Phan Thanh et al.
Background: Hallucinations, ranging from minor (MH) to structured, are a common non-motor symptom in Parkinson's disease (PD). Structured hallucinations have been associated with altered functional connectivity (FC) between dorsal/ventral attention (DAN, VAN) and default mode (DMN) networks. As structured hallucinations are linked to rapid cognitive decline and MH are often viewed as their...
medRxiv
July 10, 2026
Mindfulness mediates depressive symptom improvement during heated yoga: a secondary analysis of a randomized controlled trial
medRxiv
July 8, 2026
Paulina Clara Dagnino, Anne Maj van der Velden, Yonatan Sanz Perl et al.
Major depressive disorder (MDD) is a heterogeneous mental disorder characterised by rumination. Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment developed to target rumination and recurrence risk. Ongoing studies have begun to identify neural changes associated with treatment effects. However, the low-dimensional organisation underlying whole-brain dynamics remains...
medRxiv
July 4, 2026
Marco Zierhut, Max Alt, Inge Maria Hahne et al.
Abstract Background Negative symptoms in schizophrenia spectrum disorders (SSD) remain insufficiently treated and require novel therapeutic approaches. Oxytocin may improve negative symptoms, although its effects appear highly context-dependent according to the social salience hypothesis. We conducted a randomized, triple-blind, placebo-controlled pilot study combining intranasal oxytocin with...
medRxiv
June 24, 2026
Dhruv Adhia, Deepali Raithatha, Arron Ferguson et al.
Abstract Vayu is a mobile breathwork system comprising an iOS companion app and Apple Watch application that delivers slow, resonant breathing using screen-free haptic cues , HRV-adaptive pacing, and reflective journaling grounded in Patanjali’s five states of mind. The watchOS component provides tactile phase guidance and real-time biometric sensing (heart rate, HRV), while the iOS interface...
medRxiv
June 23, 2026
Paulina Clara Dagnino, Anne Maj van der Velden, Henricus G. Ruhé et al.
Abstract Major depressive disorder (MDD) is a leading cause of disability worldwide with risk of onset and recurrence linked to depressive ruminative thought patterns. Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment for depression that targets the ability to recognise, decenter, and disengage from ruminative thought patterns. Elucidating how MBCT impacts hierarchical...
medRxiv
June 22, 2026
Roi Basch, Maya Cohen, Leehe Peled-Avron
Abstract Background Serotonin has been implicated in cognitive flexibility and pathological perseverative thinking (PT), including rumination, worry, and obsessions. However, evidence remains fragmented across pharmacological manipulations, clinical populations, and outcome measures. This multilevel meta-analysis examined whether serotonergic interventions influence PT and cognitive...
medRxiv
June 1, 2026
Erica J. Li, Basmah Mosharraf, Hiba Ali et al.
Background: Psychedelics are emerging as potential management options for chronic musculoskeletal pain due to preliminary evidence of effectiveness and low addictive potential, but patients’ perceptions remain unknown. This study assessed patient perceptions regarding psilocybin for musculoskeletal pain. Methods: We conducted a cross-sectional survey of adults (≥19) with musculoskeletal pain...
medRxiv
April 5, 2026
Adele Pacini, Naoko Kishita, G.A. Hawkins et al.
Abstract Background Resilience is acknowledged to be an important component for successful aging in older adults, but there is scant evidence with which to inform public health interventions for this age group. The aim of this study is to determine whether the public health intervention, ‘mindfulness for later life’ is both feasible and acceptable to older adults. Methods Participants were...
medRxiv
February 19, 2026
Amanda Gow, Emily Shih, Ryan Reid et al.
Abstract Background In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using naturally-derived mushroom products. No studies have examined mental health outcomes among individuals receiving psilocybin in this context. Aims To evaluate changes in self-reported symptoms of depression, anxiety, and well-being 30-days...
medRxiv
February 17, 2026
Constantin Weberpals, A. Specht, Natasja Bonde Andersen et al.
Abstract Type 1 narcolepsy (NT1), a disorder caused by the loss of hypocretin/orexin transmission, is characterized by daytime sleepiness and symptoms where Rapid Eye Movement (REM) sleep, a state normally occurring from middle to late in the night, can intermingle with wakefulness. This results in cataplexy and sleep paralysis, episodes of muscle paralysis when awake, or in the generation of...